Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2002

01-08-2002 | Original Article

Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer

Authors: Jin-Hee Ahn, Yoon-Koo Kang, Tae-Won Kim, Haeseoung Bahng, Heung-Moon Chang, Wee-Chang Kang, Woo Kim, Jung-Shin Lee, Jung-Sik Park

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2002

Login to get access
Metadata
Title
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer
Authors
Jin-Hee Ahn
Yoon-Koo Kang
Tae-Won Kim
Haeseoung Bahng
Heung-Moon Chang
Wee-Chang Kang
Woo Kim
Jung-Shin Lee
Jung-Sik Park
Publication date
01-08-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0483-x

Other articles of this Issue 2/2002

Cancer Chemotherapy and Pharmacology 2/2002 Go to the issue

Original Article

Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment

Original Article

Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs

Original Article

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

Original Article

Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs

Short Communication

The chemokine CCL21 protects normal marrow progenitors from Ara-C cytotoxicity

Original Article

Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits